Behnam B Badie MD F.A.C.S.
Brain & Spinal Tumor, Pituitary Surgery, Skull Base
Chief, Division of Neurosurgery | Director, Brain Tumor Program | Vice Chair & Professor, Department of Surgery at City of Hope
Join to View Full Profile
Division of Neurosurgery1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-471-7344
Dr. Badie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified neurosurgeon and current vice chair & professor, Department of Surgery and chief, Division of Neurosurgery at City of Hope in Duarte, California. I am also the director of the Brain Tumor Program at City of Hope.
I am an expert in the field of surgical neuro-oncology, and our Brain Tumor Program and Division of Neurosurgery is leading groundbreaking research into nanotechnology as a tool for delivering cancer-fighting drugs directly into tumors, in a minimally invasive manner.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurological Surgery, 1990 - 1996- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Transitional Year, 1989 - 1990
David Geffen School of Medicine at UCLAClass of 1989
Certifications & Licensure
CA State Medical License 1991 - 2026
WI State Medical License 1996 - 2007
American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Start of enrollment: 2010 May 01
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Start of enrollment: 2015 May 18
- Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Start of enrollment: 2018 Aug 14
- Join now to see all
Publications & Presentations
PubMed
- Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.Patrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, Behnam Badie, Jana Portnow
Journal of Clinical Medicine. 2024-12-10 - 1 citationsAn intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.Zeynep Eroglu, Timothy Synold, Behnam Badie, An Liu, Arnab Chowdhury
Cancer Chemotherapy and Pharmacology. 2024-12-01 - Towards a Robotically Steerable Laser Ablation Probe.Julio Adrian Ceja, Saeed Rezaeian, J Rodrigo Vélez-Cordero, Juan Hernández-Cordero, Behnam Badie
... International Symposium on Medical Robotics. International Symposium on Medical Robotics. 2024-06-01
Press Mentions
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022March 9th, 2022- Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022March 9th, 2022
- City of Hope Physicians and Scientists Present New Immunotherapy Research at ASCO Virtual ConferenceJune 3rd, 2021
- Join now to see all
Grant Support
- Novel Cell Delivery Method for Brain Tumor TherapyNational Cancer Institute (NCI)2014–Present
- Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma TherapyNINDS2013–Present
- Role Of Receptor For Advanced Glycation END Product (RAGE) Pathway In Brain TumorNational Cancer Institute2011
- Application Of Carbon Nanotubes For Macrophage Activation In Brain Tumor ModelsNational Cancer Institute2009–2010
Professional Memberships
- Member
- Fellow
Other Languages
- Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
